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a  b  s  t  r  a  c  t
INTRODUCTION:  Extramedullary  plasmacytoma  (EMP)  is a  plasma  cell  neoplasm  that  presents  as  a solitary
tumor.  EMP  in  the  gastrointestinal  organs  are  extremely  uncommon.
PRESENTATION  OF  CASE:  A  36-year-old  man  was  admitted  to our  hospital  with  advanced  anemia.  He
had no speciﬁc  medical  history.  Gastroendoscopic  ﬁndings  showed  an  8.0-cm  submucosal  tumor  with
ulcer  on  the  greater  curvature  of  the  gastric  body.  Fine-needle  aspiration  was  performed,  and  the  patho-
logic  diagnosis  of  the  submucosal  tumor  was a plasmacytoma.  Therefore,  the  patient  was  diagnosed
with  gastric  plasmacytoma.  A  total  gastrectomy  was performed  with  lymphadenectomy.  The  result  of
intraoperative  peritoneal  lavage  cytology  was  positive.  Histological  examination  revealed  serosa-exposed
plasmacytoma  of the stomach  with  lymph  nodes  metastasis.  Additionaly  the  patient  received  a  three-drug
chemotherapy  regimen  (bortezomib,  cyclophosphamide,  and  dexamethasone  [VCD])  from  3 weeks  after
the  operation.  After 4 cycles  of chemotherapy,  the  patient  received  autologous  peripheral  blood  stem-cell
transplantation  (auto-PBSCT).  Eighteen  months  after  diagnosis,  the patient  is  in  complete  remission  with
no evidence  of  local  relapse  or  evolution  to  multiple  myeloma.
CONCLUSIONS:  This  is  the  ﬁrst reported  case  of advanced  gastric  plasmacytoma  using adjuvant
chemotherapy  involving  bortezomib  and  auto-PBSCT  after  the  resection,  and  the  patient  has  maintained
a  good  course  over a year.  This  protocol  could  be  a new  way  to treat these  tumors.
©  2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Extramedullary plasmacytoma (EMP) is a rare disease and is
istopathologically characterized by inﬁltrates of plasma cells of
iverse maturity and by their monoclonal immunoglobulin prod-
cts [1]. The disease occurs almost exclusively in the head, neck,
nd upper respiratory tract. EMPs in the gastrointestinal organs are
ncommon [2]. The next most frequent site of lesion occurrence is
he stomach; however, this is also extremely rare, accounting for
Abbreviations: Auto-PBSCT, autologous peripheral blood stem-cell transplan-
ation; CT, computed tomography; EMP, extramedullary plasmacytoma; ESD,
ndoscopic submucosal dissection; FDG, ﬂudeoxyglucose (18F); PET-CT, positron
mission tomography-CT; VCD, bortezomib, cyclophosphamide, and dexametha-
one; VD, bortezomib and dexamethasone.
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E-mail address: thiroes@gmail.com (H. Tazawa).
ttp://dx.doi.org/10.1016/j.ijscr.2016.08.041
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
less than 5% of all EMPs [3]. Although plasmacytoma is rare and
few cases have been reported before, the adjuvant treatment lacks
deﬁnitive guidelines. In such a situation we attempted with this
unique combination therapy and have achieved satisfactory result.
This is the ﬁrst reported case of gastric plasmacytoma treated by
combination chemotherapy (bortezomib, cyclophosphamide, and
dexamethasone [VCD]), and autologous peripheral blood stem-cell
transplantation (auto-PBSCT). Therefore we are presenting this case
highlighting a new way  to treat these tumors.
2. Presentation of case
A 36-year-old man  with dyspnea and general fatigue visited
a local doctor. Blood examination revealed advanced anemia,
and he was referred to our hospital for a detailed examination.
The results of laboratory examinations were as follows: white
blood cell count, 5150/mm3 (normal range 4500–9000); red blood
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. (a) Endoscopy showed an 8.0-cm protuberant lesion with ulcer on the greater curvature of the gastric body. (b) Magnifying narrow-band imaging endoscopy revealed
the  abnormal mucosal microstructure in the discolored protrusion (white arrows). (c) Endoscopic ultrasonography showed a hypoechoic mass deriving from the submucosal
layer.





1Fig. 3. (a, b) The resected tumor was  8.0 × 6.5 cm in size. The tumor 
4 3ell count, 234 × 10 /mm (normal range 435–555); hemoglobin
evel, 5.7 g/dL (normal range 13.6–17.0); hematocrit, 20.6% (normal
ange 40.7–50.1); platelet count, 26.8 × 104/mm3 (normal range
4.0–36.0); serum blood urea nitrogen level, 25.0 mg/dL (normalh white and elastic hard with the presence of a seroma component.range 8–20); serum creatinine level, 0.73 mg/dL (normal range
0.5–1.2); serum alkaline phosphatase level, 123 U/L (normal range
100–340); serum calcium level, 9.2 mg/dL (normal range 8.2–10.2);
and serum Fe level, 14.2 g/dL (normal range 54–181). The levels
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dig. 4. (a) Microscopic examination (hematoxylin-eosin staining, original magniﬁc
mmunohistochemical staining of the tumor cells for CD138 showed positive result
f tumor markers were within the normal ranges (carcinoembry-
nic antigen 1.0 ng/mL and CA 19–9 2.0 U/mL). The patient had no
istory of serious illness, operations, or hospitalizations. Gastroin-
estinal endoscopy showed an 8.0-cm submucosal tumor with ulcer
n the greater curvature of the gastric body (Fig. 1a). Magnifying
arrow-band imaging endoscopy revealed the abnormal mucosal
icrostructure in the discolored protrusion (Fig. 1b). Examina-
ion by color Doppler endoscopic ultrasonography showed the
ypoechoic mass with hypervascularity arising from the submu-
osal layer (Fig. 1c). Fine-needle aspiration was performed, and
he pathologic diagnosis of the submucosal tumor was  a possible
lasmacytoma of the stomach. Abdominal computed tomography
CT) revealed focal wall thickening with hyperenhancement on the
reater curvature and no sign of any lymph node swelling (Fig. 2a,
). We did not observe any accumulation of ﬂudeoxyglucose uptake
n positron emission tomography (PET)-CT, even at the lesion site
f the main stomach tumor. Bone marrow puncture and M pro-
ein identiﬁcation for the evaluation of multiple myeloma were
ormal. Testing for urinary Bence Jones protein was  negative. The
atient was diagnosed with primary gastric plasmacytoma, and we
erformed a total gastrectomy with extended removal of regional
ymph nodes (D2) speciﬁed in the Japanese classiﬁcation of gastric
ancer [4]. The result of intraoperative peritoneal lavage cytology
as positive. Histological examination revealed serosa-exposed
lasmacytoma of the stomach with 4 out of 15 lymph nodes metas-
asis. (Fig. 3a, b). The immunohistological ﬁndings showed that the
umor cells were negative for CD20, CD79a, CD3, and cyclin D1,
nd positive for CD138 (Fig. 4a, b). The Ki-67 labeling index was
igh. The surface immunoglobulin was the IgA- type. The patient
eceived combination therapy with a three-drug chemotherapy
VCD) 3 weeks after the operation. Bortezomib (1.3 mg/m2; days 1,
, 8, and 11), cyclophosphamide (1.5 g/m2; days 1–14), and dexam-
thasone (40 mg/day; days 1, 4, 8, and 11) were given in each cycle.
fter 4 cycles of the three-drug chemotherapy, the patient received
igh-dose melphalan (140 mg/m2) followed by auto-PBSCT. Eigh-
een months after diagnosis, the patient is in complete remission
ith no evidence of local relapse or evolution to multiple myeloma.
. Discussion
Plasma cell neoplasms are categorized into four groups; multi-
le myeloma, plasma cell leukemias, solitary plasmacytomas of the
one, and EMP  [3]. The diagnosis of EMP  requires demonstration of
 histologically evidence of tumor in the bone marrow. In this case,
he patient had a biopsy-proven extramedullary plasma cell tumor
ith lymph node involvement and a monoclonal band on serum
rotein electrophoresis of IgA. Bone marrow biopsy revealed less
han 5% of plasma cells. No bone lesions were found. Therefore, the
iagnosis was EMP  of the stomach. × 400) revealed numerous plasma cells inﬁltrating the serosa of the stomach. (b)
All segments of the gastrointestinal tract may  be involved
by EMPs, with the small intestine being the most common,
followed by the stomach, colon, and esophagus. Gastric plasma-
cytomas are a very rare form of EMP. Gastric tumors account
for 2–5% of all EMPs, and tend to be identiﬁed at a late stage
if an endoscopic examination is not performed [5]. Almost
all patients with EMPs are treated with radiation therapy,
surgery, or combination therapy. However, no general treatment
guidelines have been established for gastric EMPs. Additionally,
the invasiveness of these initial therapeutic approaches pre-
cludes their recommendation for EMPs of the head and neck
[6].
In this case, we  performed a total gastrectomy with D2 lym-
phadenectomy under the diagnosis of primary solid plasmacytoma
of the stomach. The pathological diagnosis was serosa-exposed
plasmacytoma (8.0 × 6.5 cm)  of the stomach with multiple lymph
nodes metastasis. The tumor was large, with lymph nodes metas-
tasis and presence of a serosa component, accompanying a positive
cytodiagnosis of ascites. In solitary plasmacytomas treated with
radiation therapy, large tumor bulk (≥50 mm)  indicates a more
progressive course and suggests a poor prognosis [7]. To our knowl-
edge, there is no report in English about the relation between
tumor progression and overall survival rate. However, one report
in Japanese from Kawata et al. [8] summarized 71 cases of primary
solid plasmacytoma of the stomach in Japan. The report detailed
disease progression in 43 patients, 15 of whom had died by the
time of publication. The invasion depth of the 15 cases had been
pT4 (SE), indicating that patients with gastric plasmacytoma with
invasion to the serosa have a markedly poorer prognosis than
the others. Most of the cases reported in the literature are early
stage of gastric plasmacytom, and these cases have been treated
with endscopic submucosal dissection [9–11]. Until now, there
has been few evidence that additional chemotherapy is beneﬁcial.
Wiltshaw et al. [12,13] reported on the effectiveness of additional
chemotherapy with melphalan, prednisone, cyclophosphamide, or
vincristine alone or in combination with complete remission rates
of 50–88%. Preud’Homme et al. reported that 20-year-old female of
huge gastric plasmacytoma had been treated with chemotherapy
(Rubidazone, procarbazine, and vinblastine) for two  years [14]. The
patient had been free of metastasis for three years after the ﬁnish-
ing chemotherapy. Katodritou et al. reported that 68-year-old male
with 5-cm gastric plasmacytoma had been treated with 4 cycle
of chemotherapy (Bortezomib and dexamethasone) [15]. Thirteen
months after the diagnosis the patient had been in complete remis-
sion with no evidence of local relapse or evolution to multiple
myeloma. Zhao et al. reported that 79-year-old male with 16-
cm gastric plasmacytoma inﬁltrating the lamina propria received
surgery consisted of total gastrectomy with a subtotal pancrea-
tectomy, splenectomy, and oesophageal and jejunum Roux-en-Y
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nastomosis [16]. There was no indication of recurrence or
etastasis at eight momths after the operation. Some EMP  cases
re known to develop multiple myeloma. After treatment of
MP in non-upper aerodigestive regions, 21.2% of patients had
ecurrence and 14.1% of them converted to multiple myeloma
3]. High-dose chemotherapy (bortezomib) with auto-PBSCT is a
tandard treatment for young patients with multiple myeloma.
he condition typically follows a relapsing course, and many
atients require multiple lines of therapy. In this case, this
atient was so young and the tumor was large, with lymph
odes metastasis and presence of a serosa component, accom-
anying a positive cytodiagnosis of ascites which indicated high
isk to develop multiple myeloma. From the above reasons, we
ttempted with high-dose chemotherapy including bortezomib
nd auto-PBSCT after the resection. The combination of borte-
omib and dexamethasone (VD), alone or with cyclophosphamide
VCD), has shown good efﬁcacy and tolerability in patients with
elapsed or refractory multiple myeloma in non-randomized trials
17,18]. We  performed combination therapy with VCD and auto-
BSCT after the operation because of the advanced pathological
esults. This combination was well tolerated and induced com-
lete and sustained remission. The only documented side effect
as transient mild neutropenia and thrombocytopenia. The use
f bortezomib, with or without dexamethasone, could be a reli-
ble, safe, and effective alternative for treating extramedullary
lasmacytomas. Sixteen months after diagnosis, the patient is in
omplete remission with no evidence of local relapse or evo-
ution to multiple myeloma. This is the ﬁrst reported case of
uccessful management of advanced EMP  of the stomach with
he combination of surgical resection and chemotherapy (VCD and
uto-PBSCT).
. Conclusion
No general treatment guidelines have been established for pri-
ary gastric plasmacytoma. We  performed combination therapy
or the advanced gastric plasmacytoma using adjuvant chemother-
py involving bortezomib and auto-PBSCT after the resection, and
he patient has maintained a good course over a year. This protocol
ould be a new way to treat these tumors.
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